Accelerate Diagnostics (NASDAQ:AXDX) & Avantor (NASDAQ:AVTR) Financial Analysis

Accelerate Diagnostics (NASDAQ:AXDX) and Avantor (NYSE:AVTR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Insider & Institutional Ownership

50.6% of Accelerate Diagnostics shares are owned by institutional investors. 47.6% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Accelerate Diagnostics and Avantor’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accelerate Diagnostics -1,352.80% -130.94% -45.98%
Avantor N/A N/A N/A

Valuation & Earnings

This table compares Accelerate Diagnostics and Avantor’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Accelerate Diagnostics $5.67 million 194.50 -$88.33 million ($1.62) -12.50
Avantor N/A N/A N/A N/A N/A

Avantor has lower revenue, but higher earnings than Accelerate Diagnostics.

Analyst Recommendations

This is a breakdown of recent ratings for Accelerate Diagnostics and Avantor, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accelerate Diagnostics 0 2 1 0 2.33
Avantor 0 2 18 0 2.90

Accelerate Diagnostics currently has a consensus price target of $19.00, indicating a potential downside of 6.17%. Avantor has a consensus price target of $20.81, indicating a potential upside of 9.25%. Given Avantor’s stronger consensus rating and higher possible upside, analysts clearly believe Avantor is more favorable than Accelerate Diagnostics.

Summary

Avantor beats Accelerate Diagnostics on 6 of the 9 factors compared between the two stocks.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

About Avantor

Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit